Short answer
Inmune Bio, Inc. (INMB) filed an 8-K current report with the SEC on February 23, 2026 reporting Item 8.01 (Other Events). Webinar Feb 27, 2026 at 9:30 a.m. ET covering XPro1595 registrational pathway for early Alzheimer's disease.
Inmune Bio, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Webinar Feb 27, 2026 at 9:30 a.m. ET covering XPro1595 registrational pathway for early Alzheimer's disease
- Registrational pathway detail signals INMB advancing toward pivotal trial or FDA approval strategy for XPro™
- Key catalyst event: investor focus on regulatory timeline and trial design specifics to be disclosed
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Inmune Bio, Inc. 8-K filings
Get the next INMB 8-K as it lands
Follow INMB for push alerts, or ask the research agent what this filing means.